NEW YORK (GenomeWeb News) – Sundance Diagnostics today announced an exclusive, worldwide licensing deal with the Max Planck Institute of Psychiatry aimed at developing and commercializing a genetic test for predicting the risk of suicide from use of antidepressants.

Sundance will validate and commercialize the test, which is based on a set of biomarkers discovered by researchers at Max Planck. The Boulder, Colo.-based company plans to launch the test as a laboratory-developed test in the US and Europe and will provide an update on its availability in early 2014.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.